Immunovia publ AB (IMMNOV) — Cash Flow-to-Debt Ratio
Immunovia publ AB (IMMNOV) has a Cash Flow-to-Debt Ratio of -0.84x as of December 2025, meaning its operating cash flow of Skr-19.78 Million could theoretically repay -1% of its total liabilities (Skr23.48 Million) in one year. See Immunovia publ AB working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Immunovia publ AB Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Immunovia publ AB across 13 annual periods. Also explore IMMNOV net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Immunovia publ AB (2013–2025)
Year-by-year debt coverage analysis for Immunovia publ AB. For market capitalisation and broader financial context, see market cap of Immunovia publ AB.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.34x | Skr-78.40 Million | Skr23.48 Million | ▲ +26.2% |
| 2024 | -4.52x | Skr-96.75 Million | Skr21.39 Million | ▲ +2.5% |
| 2023 | -4.64x | Skr-147.06 Million | Skr31.69 Million | ▼ -50.1% |
| 2022 | -3.09x | Skr-175.58 Million | Skr56.79 Million | ▼ -21.3% |
| 2021 | -2.55x | Skr-152.65 Million | Skr59.91 Million | ▼ -30.4% |
| 2020 | -1.95x | Skr-120.70 Million | Skr61.77 Million | ▼ -31.2% |
| 2019 | -1.49x | Skr-91.95 Million | Skr61.76 Million | ▲ +72.7% |
| 2018 | -5.45x | Skr-84.11 Million | Skr15.43 Million | ▼ -64.5% |
| 2017 | -3.31x | Skr-46.32 Million | Skr13.97 Million | ▼ -89.3% |
| 2016 | -1.75x | Skr-11.87 Million | Skr6.78 Million | ▼ -374.6% |
| 2015 | -0.37x | Skr-2.84 Million | Skr7.71 Million | ▲ +86.1% |
| 2014 | -2.65x | Skr-8.29 Million | Skr3.13 Million | ▼ -1514.7% |
| 2013 | -0.16x | Skr-414.31K | Skr2.53 Million | — |